165 related articles for article (PubMed ID: 23654144)
21. Severe autoimmune hemolytic anemia in a patient with chronic hepatitis C during treatment with Peg interferon alfa-2a and ribavirin.
Ennaifer R; Cheikh M; Romdhane H; Hefaiedh R; Ben Nejma H; Bel Hadj N
Tunis Med; 2014 Jan; 92(1):42-3. PubMed ID: 24879173
[No Abstract] [Full Text] [Related]
22. [Pegylated interferon and ribavirin associated retinopathy in patients with hepatitis C].
Burgueño-Montañés C; Pérez-Álvarez R
Arch Soc Esp Oftalmol; 2011 Jun; 86(6):193-5. PubMed ID: 21767697
[TBL] [Abstract][Full Text] [Related]
23. Alopecia universalis as a side effect of pegylated interferon α-ribavirin combination therapy for hepatitis C: a rare case report.
Verma P; Dayal S; Jain VK; Amrani A
J Chemother; 2017 Dec; 29(6):380-382. PubMed ID: 27741937
[TBL] [Abstract][Full Text] [Related]
24. Severe anaemia related to oseltamivir during treatment of chronic hepatitis C: a new drug interaction?
Simón-Talero M; Buti M; Esteban R
J Viral Hepat; 2012 Jan; 19 Suppl 1():14-7. PubMed ID: 22233409
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of peginterferon α-2a (40 KD) plus ribavirin in treatment-naive chronic hepatitis C patients in Central and Eastern Europe.
Urbanek P; Oltman M; Ivanovski L; Rehák V; Messinger D; Tietz A; Husa P
Eur J Gastroenterol Hepatol; 2011 Nov; 23(11):1004-10. PubMed ID: 21904204
[TBL] [Abstract][Full Text] [Related]
26. Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin.
Antonini MG; Babudieri S; Maida I; Baiguera C; Zanini B; Fenu L; Dettori G; Manno D; Mura MS; Carosi G; Puoti M
Infection; 2008 Jun; 36(3):250-5. PubMed ID: 18458815
[TBL] [Abstract][Full Text] [Related]
27. Safety of peginterferon alfa-2a plus ribavirin in a large multinational cohort of chronic hepatitis C patients.
Lee SS; Roberts SK; Berak H; Dusheiko GM; Harley HA; Gane EJ; Husa P; Horsmans YJ; Hadziyannis SJ; Jenny Heathcote E; Messinger D; Tatsch F; Han KH; Ferenci P
Liver Int; 2012 Sep; 32(8):1270-7. PubMed ID: 22621707
[TBL] [Abstract][Full Text] [Related]
28. Interstitial pneumonitis during combination therapy with interferon-alpha and ribavirin in a patient with chronic Hepatitis C.
Rothfuss KS; Bode JC
Z Gastroenterol; 2002 Sep; 40(9):807-10. PubMed ID: 12215950
[TBL] [Abstract][Full Text] [Related]
29. Treatment of hepatitis C virus infection in patients on maintenance hemodialysis: a single United Arab Emirates center experience.
Giguere A; Anas A; Nasser T; Hassan MH; Ahmed U; Beejay N; Nouh M; Khalowf M; Saleh A; Khan A; Attia M; El-Azab G
Eur J Intern Med; 2011 Dec; 22(6):582-6. PubMed ID: 22075284
[TBL] [Abstract][Full Text] [Related]
30. Chronic hepatitis C genotype 1 patients with insulin resistance treated with pioglitazone and peginterferon alpha-2a plus ribavirin.
Harrison SA; Hamzeh FM; Han J; Pandya PK; Sheikh MY; Vierling JM
Hepatology; 2012 Aug; 56(2):464-73. PubMed ID: 22334369
[TBL] [Abstract][Full Text] [Related]
31. A case of irreversible leukoencephalopathy in a patient with C virus hepatitis treated with pegylated interferon-alpha-2b and ribavirin.
Iacob SA; Petrescu AM; Iacob DG
Rom J Intern Med; 2013; 51(3-4):197-200. PubMed ID: 24620633
[TBL] [Abstract][Full Text] [Related]
32. Thyroid function and changes in ultrasound morphology during antiviral therapy with pegylated interferon and ribavirin in patients with chronic hepatitis C.
Friedrich-Rust M; Theobald J; Zeuzem S; Bojunga J
J Viral Hepat; 2009 Mar; 16(3):168-77. PubMed ID: 19175874
[TBL] [Abstract][Full Text] [Related]
33. [Probable cutaneous sarcoidosis associated with combined ribavirin and interferon-alpha therapy for chronic hepatitis C].
Savoye G; Goria O; Herve S; Riachi G; Noblesse I; Bastien L; Courville P; Lerebours E
Gastroenterol Clin Biol; 2000; 24(6-7):679. PubMed ID: 10962394
[No Abstract] [Full Text] [Related]
34. Taste disturbances during therapy with pegylated interferon-alpha 2b and ribavirin in patients with chronic hepatitis C.
Klimacka-Nawrot E; Musialik J; Suchecka W; Petelenz M; Hartman M; Lichtański P; Błońska-Fajfrowska B
Wiad Lek; 2010; 63(4):289-99. PubMed ID: 21608370
[TBL] [Abstract][Full Text] [Related]
35. Unilateral hearing loss due to pegylated interferon-α2b and ribavirin therapy.
Jain S; Midha V; Sood A
Indian J Gastroenterol; 2011 Sep; 30(5):239-40. PubMed ID: 21986854
[No Abstract] [Full Text] [Related]
36. Cutaneous sarcoidosis developing after treatment with pegylated interferon and ribavirin: a new case and review of the literature.
López V; Molina I; Monteagudo C; Jordá E
Int J Dermatol; 2011 Mar; 50(3):287-91. PubMed ID: 21342161
[TBL] [Abstract][Full Text] [Related]
37. Is combination therapy interferon and ribavirin in patients with chronic hepatitis C infection toxic for eyes?
Mousa N; Besheer T; Gad Y; Elbendary A; Mokbel T; Abdel-Aziz A
J Ocul Pharmacol Ther; 2013 Apr; 29(3):345-8. PubMed ID: 23113644
[TBL] [Abstract][Full Text] [Related]
38. Concurrent acute interstitial pneumonia and pulmonary embolism during treatment with peginterferon alpha-2a and ribavirin in a patient with hepatitis C.
Coban H; Yahyaoglu M; Vatan MB
Indian J Pharmacol; 2014; 46(4):443-5. PubMed ID: 25097288
[TBL] [Abstract][Full Text] [Related]
39. Does the antiviral therapy of patients with chronic hepatitis exert nephrotoxic effects?
Gluhovschi C; Gadalean F; Kaycsa A; Curescu M; Sporea I; Gluhovschi G; Petrica L; Velciov S; Bozdog G; Bob F; Vernic C; Cioca D
Immunopharmacol Immunotoxicol; 2011 Dec; 33(4):744-50. PubMed ID: 21320001
[TBL] [Abstract][Full Text] [Related]
40. Randomized trial of peginterferon alpha-2b plus low and escalating dose of ribavirin in patients with chronic hepatitis C with high viral load genotype 1.
Iwasaki Y; Araki Y; Taniguchi H; Okamoto R; Kobashi H; Ikeda F; Miyake Y; Takaki A; Yamamoto K
J Med Virol; 2015 Apr; 87(4):625-33. PubMed ID: 25611729
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
